Safety profile of IBD: lymphoma risks.
This article describes the cancer risks of commonly used inflammatory bowel disease (IBD) medications, with an emphasis on hematologic malignancy risks. The increasing use of immunosuppressant therapies in the treatment of IBD has raised this question to an even greater importance. Studies evaluating these medications are complicated due to varying disease severity and concomitant use of other immunosuppressant medication. The potential risks of all therapies must be weighed against the benefits these therapies can offer these patients.
Bewtra
Meenakshi
M
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA. meenakshi.bewtra@uphs.upenn.edu
Lewis
James D
JD
D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000145:classification*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008223:Lymphoma / Q000139:chemically induced*; D012307:Risk Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents